Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q2 2020 Earnings Conference Call - Final Transcript

Aug 05, 2020 • 11:30 am ET

Previous

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q2 2020 Earnings Conference Call - Final Transcript

Share
Close

Loading Event

Loading Transcript

Presentation
Operator
Operator

Good morning and welcome to Ionis Pharmaceuticals Second Quarter 2020 Financial Results Conference Call. As a reminder, this call is being recorded.

At this time, I would like to turn the call over to Wade Walke, Vice President, Investor Relations, to lead off the call. Please, begin.

Executive
Wade Walke

Thank you, Ailey [Phonetic]. Before we begin, I encourage everyone to go to the Investors section of the Ionis website to find the press release and related financial tables, including a reconciliation of the GAAP to non-GAAP financial measures that we will discuss today. We believe non-GAAP financial measures better represent the economics of our business and how we manage our business. We've also posted slides on our website that accompany our discussion today.

With me on today's call are Brett Monia, Chief Executive Officer; Beth Hougen, Chief Financial Officer; and Richard Geary, Executive Vice President of Development. Additionally, joining us for Q&A are, Onaiza Cadoret, Chief Corporate Development and Commercial Officer; and Eric Swayze, Executive Vice President of Research.

I'd like to draw your attention to slide three, which contains our forward-looking language statement. We will begin by making forward-looking -- we will be making forward-looking statements which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties and our actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for additional detail.

And with that, I'll turn the call over to Brett.

Executive
Brett Monia

Thanks, Wade. Good morning and thank you for joining us on today's call. The first half of this year was marked by numerous important achievements that position us well for success this year and in the future. This has been a remarkable year for many reasons, but in particular, for the tremendous strength and dedication demonstrated by the Ionis team. Our hard work has enabled us to remain on track to meet our key 2020 goals and achieved great success for years to come. And as we enter the second half of this year, I believe, we are stronger than ever.

Our Phase three programs are on track with five studies in progress and two additional registration studies expected to start this year. Our mid and early-stage medicines are making excellent progress, with additional proof-of-concept data for several programs due later this year. We continue to grow and expand the scope of our clinical pipeline with new medicines advancing rapidly to treat many new diseases, for which effective treatments are lacking. We also continue to grow the Iona selling pipeline. While, in parallel, developing our commercialization strategy and support of this pipeline and we continue to advance and expand the reach of our technology at a record pace.

Looking ahead, we remain on track to achieve our 2020 financial guidance and we have the financial resources, the people and the commitment to execute on our agenda. My vision for Ionis is to lead our industry in bringing transformative medicines to patients suffering with devastating diseases.